Clinical Trial Update: Effect of Sitagliptin on Progression of Coronary Intermediate Lesion [Phase 4]

View source ↗

Summary

Phase 4 trial update on sitagliptin's effect on progression of coronary intermediate lesions in patients with atherosclerosis and type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Type 2 Diabetes Mellitus

Drugs mentioned

• Sitagliptin (sitagliptin)

Snippet

Sponsor: Li Bo | Conditions: Atherosclerosis, Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED